Traditional Chinese medicine combined with low-dose anlotinib therapy for chordoma: A case report
1.Beijing University of Chinese Medicine, Beijing 100029
2.Xi yuan Hospital, China Academy of Chinese Medical Sciences
3.Fang shan Hospital of Beijing University of Chinese Medicine
DOI:
扫 描 看 全 文
Zhao Na, Pei Xiaohua, Yang Yufei. Traditional Chinese medicine combined with low-dose anlotinib therapy for chordoma: A case report[DB/OL].(2023-09-15)[2023-11-05].http://cccl-tcm.cacm.org.cn/thesisDetails?columnId=32290641&Fpath=home&index=0
DOI:
Zhao Na, Pei Xiaohua, Yang Yufei. Traditional Chinese medicine combined with low-dose anlotinib therapy for chordoma: A case report[DB/OL].(2023-09-15)[2023-11-05].http://cccl-tcm.cacm.org.cn/thesisDetails?columnId=32290641&Fpath=home&index=0DOI:
Traditional Chinese medicine combined with low-dose anlotinib therapy for chordoma: A case report
Chordoma is a rare subtype of bone cancer. Wide resection with negative surgical margins and radiotherapy are the main effective treatment methods. Although there is no preferred regimen for chordoma, the targeted therapy can still be recommended. On the basis of traditional Chinese medicine (TCM) syndrome differentiation and treatment, Professor Yang Yufei combines TCM treatment with the low-dose targeted therapy to achieve PFS for 12 months in a chordoma case. This article may help inherit valuable experience of TCM experts and take advantage of TCM in the clinical practice for chordoma.
关键词
脊索瘤辨证论治中医治疗靶向治疗
Keywords
chordomaTCM syndrome differentiation and treatmentTCM treatmenttargeted therapy
references
YOUNG VA, CURTIS KM, TEMPLE HT, et al. Characteristics and Patterns of Metastatic Disease from Chordoma[J]. Sarcoma, 2015:517-657.
GEORGE B, BRESSON D, HERMAN P, et al. Chordomas: A Review[J]. Neurosurg Clin N Am, 2015, 26(3):437-452.
SMOLL N R, GAUTSCHI O P, RADOVANOVIC I, et al.Incidence and relative survival of chordomas: the standardized mortality ratio and the impact of chordomas on a population[J]. Cancer, 2013,119(11):2029-2037.
SCIUBBA D M, CHI J H, RHINES L D, et al. Chordoma of the spinal column[J]. Neurosurg Clin N Am, 2008, 19(1):5-15.
NCCN. The NCCN Clinical Practice Guidelines in Oncology Bone Cancer (Version 1.2020)[EB/OL].Fort Washington: NCCN, 2020[2019-8-12]. http: //www.nccw.org.
BERGH P, KINDBLOM L G, GUNTERBERG B, et al.Prognostic factors in chordoma of the sacrum and mobile spine: a study of 39 patients[J]. Cancer, 2000, 88(9):2122-2134.
CHEN KW, YANG HL, LU J, et al.Prognostic factors of sacral chordoma after surgical therapy: a study of 36 patients[J]. Spinal Cord, 2010, 48(2):166-171.
STACCHIOTTI S, CASALI P G, LO VULLO S, et al.Chordoma of the mobile spine and sacrum: a retrospective analysis of a series of patients surgically treated at two referral centers[J]. Ann Surg Oncol, 2010,17(1):211-219.
RUGGIERI P, ANGELINI A, USSIA G, et al.Surgical margins and local control in resection of sacral chordomas[J]. Clin Orthop Relat Res. 2010, 468(11):2939-2947.
ROTONDO R L, FOLKERT W, LIEBSCH N J, et al.High-dose proton-based radiation therapy in the management of spine chordomas: outcomes and clinicopathological prognostic factors[J]. J Neurosurg Spine, 2015, 23(6):788-797.
UHL M, EDLER L, JENSEN A D, et al.Randomized phase II trial of hypofractionated proton versus carbon ion radiation therapy in patients with sacrococcygeal chordoma-the ISAC trial protocol[J]. Radiat Oncol, 2014, 29(9):100.
MIMA M, DEMIZU Y, JIN D, et al.Particle therapy using carbon ions or protons as a definitive therapy for patients with primary sacral chordoma[J]. Br J Radiol, 2014,87(1033):20130512.
YORK JE, KACZARAJ A, ABI-SAID D, et al.Sacral chordoma: 40-year experience at a major cancer center[J]. Neurosurgery, 1999,44(1):74-9; discussion 79-80.
COLIA V, STACCHIOTTI S. Medical treatment of advanced chordomas[J]. Eur J Cancer, 2017, 83:220-228.
YANG C, HORNICEK F J, WOOD K B, et al.Characterization and analysis of human chordoma cell lines[J]. Spine, 2010, 35(13):1257-1264.
SéGALINY A I, TELLEZ-GABRIEL M, HEYMANN M F, et al.Receptor tyrosine kinases: Characterisation, mechanism of action and therapeutic interests for bone cancers[J]. J Bone Oncol, 2015, 4(1):1-12.
AKHAVAN-SIGARI R, ABILI M, GAAB M R, et al.Immunohistochemical expression of receptor tyrosine kinase PDGFR-α,c-Met, and EGFR in skull base chordoma[J]. Neurosurg Rev, 2015,38(1):89-98; discussion 98-9.
FASIG J H, DUPONT W D, LAFLEUR B J, et al.Immunohistochemical analysis of receptor tyrosine kinase signal transduction activity in chordoma[J]. Neuropathol Appl Neurobiol, 2008, 34(1):95-104.
SHALABY A, PRESNEAU N, YE H, et al.The role of epidermal growth factor receptor in chordoma pathogenesis: a potential therapeutic target[J]. J Pathol. 2011 Feb;223(3):336-346.
LINDéN O, STENBERG L, KJELLéN E. Regression of cervical spinal cord compression in a patient with chordoma following treatment with cetuximab and gefitinib[J]. Acta Oncol, 2009,48(1):158-159.
LAUNAY S G, CHETAILLE B, MEDINA F, et al.Efficacy of epidermal growth factor receptor targeting in advanced chordoma: case report and literature review[J]. BMC Cancer, 2011,11:423.
NOOR A, BINDAL P, RAMIREZ M, et al.Chordoma: A Case Report and Review of Literature[J]. Am J Case Rep, 2020 Jan 23;21:e918927.
STACCHIOTTI S, LONGHI A, FERRARESI V, et al.Phase II study of imatinib in advanced chordoma[J]. J Clin Oncol, 2012, 30(9):914-920.
HINDI N, CASALI P G, MOROSI C, et al.Imatinib in advanced chordoma: a retrospective case series analysis[J]. Eur J Cancer, 2015,51(17):2609-2614.